July 1, 2025
| Today’s news and insights for biopharma leaders
State of Play
The success of Vertex's opioid alternative Journavx could aid a group of biotechs that aim to take a similar path with NaV1.8 and NaV1.7 inhibitors.
|
Positive study results in Phase 2 lead to a green light for the companies’ combination and plans to move their nasal spray into pivotal testing.
|
The biotech, which agreed to be bought by Supernus after clinical and commercial struggles, plans to lay off 338 employees by late August.
|
Patent protection will run out later this decade for many multibillion-dollar medicines and will force their large pharmaceutical makers to find new products and markets. Explore their strategies in
|
UPDATED
Expected readouts in obesity, lung cancer and atopic dermatitis headline a series of study results that could give the biotechnology sector a boost.
|
The acquisition will expand AbbVie's exploration of in vivo CAR-T therapy, an ambitious approach that could sidestep some of the difficulties presented by current cell treatments.
|
|
GSK transformed drug development by investing in claims data early and revealing critical treatment dynamics. Learn their approach to securing budget, maximizing ROI and de-risking programs in this webinar.
|
|
From Our Library
Webinar - on demand
Custom content for MMIT
|
Survey Report
Custom content for TriNetX
|
Playbook
Custom content for Inovalon
|
View all resources
What We’re Reading
| 
